Advertisement
Screener

Zoetis Inc. (ZTS) ROE

Zoetis Inc. ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Zoetis Inc. roe for the quarter ending 2026-06-30 was 83.10%, a 65.46% increase year-over-year.
  • Zoetis Inc. roe for the quarter ending 2026-03-31 was 82.00%, a 60.27% increase year-over-year.
  • Zoetis Inc. roe for the quarter ending 2025-12-31 was 77.66%, a 51.32% increase year-over-year.
  • Zoetis Inc. roe for the quarter ending 2025-09-30 was 48.72%, a 4.94% increase year-over-year.
  • Zoetis Inc. roe for fiscal 2025 was 80.25%, a 53.97% increase from fiscal 2024.
  • Zoetis Inc. roe for fiscal 2024 was 52.12%, a 10.97% increase from fiscal 2023.
  • Zoetis Inc. roe for fiscal 2023 was 46.96%, a 2.18% decline from fiscal 2022.
  • Zoetis Inc. roe for fiscal 2022 was 48.01%, a 7.10% increase from fiscal 2021.
Available history
2011-12-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-3083.10%$2.62B$691.00M$3.15B
2026-03-3182.00%$2.65B$601.00M$3.23B
2025-12-3177.66%$2.65B$603.00M$3.42B
2025-09-3048.72%$2.63B$721.00M$5.4B
2025-06-3050.22%$2.59B$726.00M$5.16B
2025-03-3151.16%$2.49B$602.00M$4.87B
2024-12-3151.32%$2.49B$581.00M$4.84B
2024-09-3046.43%$2.43B$682.00M$5.23B
2024-06-3047.26%$2.34B$624.00M$4.96B
2024-03-3147.33%$2.39B$599.00M$5.05B
2023-12-3146.96%$2.34B$525.00M$4.99B
2023-09-3044.93%$2.28B$596.00M$5.07B
2023-06-3047.89%$2.21B$671.00M$4.62B
2023-03-3146.11%$2.07B$552.00M$4.49B
2022-12-3148.01%$2.11B$461.00M$4.4B
2022-09-3044.34%$2.07B$529.00M$4.66B
2022-06-3045.63%$2.09B$529.00M$4.58B
2022-03-3144.50%$2.07B$595.00M$4.66B
2021-12-3144.83%$2.04B$414.00M$4.54B
2021-09-3042.34%$1.98B$552.00M$4.68B
2021-06-3043.86%$1.91B$512.00M$4.35B
2021-03-3143.35%$1.77B$559.00M$4.09B
2020-12-3143.41%$1.64B$359.00M$3.77B
2020-09-3046.10%$1.66B$479.00M$3.61B
2020-06-3054.13%$1.62B$377.00M$2.99B
2020-03-3158.52%$1.61B$423.00M$2.75B
2019-12-3155.39%$1.5B$384.00M$2.71B
2019-09-3054.56%$1.46B$433.00M$2.68B
2019-06-3057.03%$1.38B$371.00M$2.41B
2019-03-3159.91%$1.39B$312.00M$2.32B
2018-12-3165.35%$1.43B$345.00M$2.19B
2018-09-3054.96%$1.16B$347.00M$2.12B
2018-06-3056.26%$1.12B$384.00M$1.98B
2018-03-3149.52%$978M$352.00M$1.98B
2017-12-3148.38%$864M$81.00M$1.79B
2017-10-0146.41%$937M$298.00M$2.02B
2017-07-0250.29%$878M$247.00M$1.75B
2017-04-0252.29%$855M$238.00M$1.64B
2016-12-3154.77%$821M$154.00M$1.5B
2016-10-0243.12%$689M$239.00M$1.6B
2016-07-0346.61%$639M$224.00M$1.37B
2016-04-0331.84%$378M$204.00M$1.19B
2015-12-3131.07%$339M$22.00M$1.09B
2015-09-2735.33%$443M$189.00M$1.25B
2015-06-2834.94%$420M-$37.00M$1.2B
2015-03-2945.44%$593M$165.00M$1.31B
2014-12-3143.61%$583M$126.00M$1.34B
2014-09-2840.46%$562M$166.00M$1.39B
2014-06-2941.08%$527M$136.00M$1.28B
2014-03-3047.22%$519M$155.00M$1.1B
2013-12-3152.39%$504M$105.00M$962M
2013-09-2944.92%$389M$131.00M$866M
2013-06-3051.03%$420M$128.00M$823M
2013-03-3164.23%$465M$140.00M$724M
2012-12-3110.79%$436M-$10.00M$4.04B

Annual ROE

DateROENet income 12 monthShareholder equity
2025-12-3180.25%$2.67B$3.33B
2024-12-3152.12%$2.49B$4.77B
2023-12-3146.96%$2.34B$4.99B
2022-12-3148.01%$2.11B$4.4B
2021-12-3144.83%$2.04B$4.54B
2020-12-3143.41%$1.64B$3.77B
2019-12-3155.39%$1.5B$2.71B
2018-12-3165.35%$1.43B$2.19B
2017-12-3148.38%$864M$1.79B
2016-12-3154.77%$821M$1.5B
2015-12-3131.07%$339M$1.09B
2014-12-3143.61%$583M$1.34B
2013-12-3152.39%$504M$962M
2012-12-3110.79%$436M$4.04B
2011-12-316.56%$245M$3.74B

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10